Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept

Vera Therapeutics, Inc. (NASDAQ:VERA) is among the 14 best booming stocks to buy right now. On January 7, the company announced that the U.S. Food and Drug Administration (FDA) had accepted Atacicept’s Biologics License Application (BLA) for priority review to treat adult patients of immunoglobulin A nephropathy (IgAN).

The application was submitted under the Accelerated Approval Program and has been granted a target action date of July 7, 2026. The drug’s approval by the FDA would let patients administer their treatments at home through an injection to be used once a week.

Vera Therapeutics, Inc. (NASDAQ:VERA)’s founder and CEO, Marshall Fordyce, M.D., believes the approval would help in enhancing the care of IgAN, as Atacicept would become the first B-cell modulator that simultaneously targets both APRIL and BAFF.

Recent findings from the ORIGIN 3 trial demonstrated the efficacy of Atacicept, with participants treated with the drug experiencing a 46% decline in proteinuria from baseline and a 42% reduction in urine protein-to-creatinine ratio compared with placebo at week 36.

Vera Therapeutics, Inc. (NASDAQ:VERA)’s shares have returned nearly 53% over the past three months, and Wall Street’s average one-year share price target of $74.08 projects a further upside of 59.45% ahead, as of January 12.

Recent analyst updates include Guggenheim and LifeSci Capital reiterating their Buy ratings on the stock on January 7, with price targets of $56 and $70, respectively.

Vera Therapeutics, Inc. (NASDAQ:VERA) is a clinical-stage biotech company that develops treatments for complex immunological diseases.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.